Myles Wolf

List of Publications by Year
in descending order

268 papers	27,899 citations	8172 76 h-index	5677 162 g-index
270 all docs	270 docs citations	270 times ranked	17965 citing authors

#	Article	IF	Citations
1	Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation, 2008, 117, 503-511.	1.6	2,077
2	FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation, 2011, 121, 4393-4408.	3.9	1,684
3	Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis. New England Journal of Medicine, 2008, 359, 584-592.	13.9	1,546
4	Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, The, 2010, 376, 180-188.	6.3	1,385
5	Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International, 2011, 79, 1370-1378.	2.6	1,004
6	Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2011, 305, 2432.	3.8	890
7	Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. New England Journal of Medicine, 2003, 349, 446-456.	13.9	870
8	Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2205-2215.	3.0	791
9	Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study. Journal of the American Society of Nephrology: JASN, 2005, 16, 1115-1125.	3.0	756
10	Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation, 2009, 119, 2545-2552.	1.6	747
11	Effects of Phosphate Binders in Moderate CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1407-1415.	3.0	486
12	Adiposity, Cardiometabolic Risk, and Vitamin D Status: The Framingham Heart Study. Diabetes, 2010, 59, 242-248.	0.3	437
13	Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metabolism, 2015, 22, 1020-1032.	7.2	432
14	First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 770-775.	1.8	395
15	Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 349-360.	3.0	380
16	Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney International, 2016, 89, 135-146.	2.6	370
17	Phosphorus Binders and Survival on Hemodialysis. Journal of the American Society of Nephrology: JASN, 2009, 20, 388-396.	3.0	341
18	Calciphylaxis from Nonuremic Causes. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1139-1143.	2.2	337

#	Article	IF	Citations
19	Update on fibroblast growth factor 23 in chronic kidney disease. Kidney International, 2012, 82, 737-747.	2.6	320
20	Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Journal of Bone and Mineral Research, 2013, 28, 1793-1803.	3.1	317
21	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney International, 2013, 83, 1159-1168.	2.6	291
22	Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney International, 2016, 90, 985-996.	2.6	284
23	Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1427-1435.	3.0	265
24	Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality. Journal of the American Society of Nephrology: JASN, 2011, 22, 956-966.	3.0	253
25	Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiology, 2017, 2, 635.	3.0	251
26	Klotho and Phosphate Are Modulators of Pathologic Uremic Cardiac Remodeling. Journal of the American Society of Nephrology: JASN, 2015, 26, 1290-1302.	3.0	231
27	Fibroblast Growth Factor 23 and Inflammation in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1155-1162.	2.2	217
28	First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes. Diabetes Care, 2003, 26, 819-824.	4.3	215
29	Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2013, 62, 670-678.	2.1	207
30	Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 578-585.	1.8	205
31	Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6239-6243.	1.8	190
32	First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1563-1568.	1.8	182
33	Patients with Fabry disease on dialysis in the United States. Kidney International, 2002, 61, 249-255.	2.6	172
34	Coupling fibroblast growth factor 23 production and cleavage. Current Opinion in Nephrology and Hypertension, 2014, 23, 411-419.	1.0	172
35	Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nature Reviews Nephrology, 2014, 10, 268-278.	4.1	166
36	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. JAMA - Journal of the American Medical Association, 2020, 323, 432.	3.8	162

#	Article	IF	Citations
37	FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nature Reviews Nephrology, 2020, 16, 7-19.	4.1	157
38	Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 1379-1388.	3.0	156
39	Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 584-591.	0.4	153
40	Genetic Variants and Associations of 25-Hydroxyvitamin D Concentrations With Major Clinical Outcomes. JAMA - Journal of the American Medical Association, 2012, 308, 1898.	3.8	153
41	Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney International, 2013, 84, 776-785.	2.6	147
42	Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 615-623.	3.0	143
43	Race, Genetic Ancestry, and Estimating Kidney Function in CKD. New England Journal of Medicine, 2021, 385, 1750-1760.	13.9	142
44	FGF-23: More than a regulator of renal phosphate handling?. Journal of Bone and Mineral Research, 2010, 25, 2091-2097.	3.1	141
45	Fibroblast Growth Factor 23, Cardiovascular Disease Risk Factors, and Phosphorus Intake in the Health Professionals Follow-up Study. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2871-2878.	2.2	139
46	Disordered FGF23 and Mineral Metabolism in Children with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 344-353.	2.2	128
47	Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight, 2018, 3, .	2.3	127
48	Interpreting Cardiac Troponin Results from High-Sensitivity Assays in Chronic Kidney Disease without Acute Coronary Syndrome. Clinical Chemistry, 2012, 58, 1342-1351.	1.5	125
49	Effects of Dietary Phosphate Restriction and Phosphate Binders on FGF23 Levels in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1009-1018.	2.2	125
50	Postpartum Diabetes Screening in Women With a History of Gestational Diabetes. Obstetrics and Gynecology, 2005, 106, 1297-1303.	1.2	123
51	A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5. American Journal of Kidney Diseases, 2015, 65, 728-736.	2.1	117
52	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 2328-2339.	3.0	116
53	Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 2015, 66, 258-265.	2.1	116
54	Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. American Journal of Obstetrics and Gynecology, 2005, 193, 16-22.	0.7	115

#	Article	IF	Citations
55	Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 579-590.	3.0	114
56	Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia. Hypertension, 2007, 49, 612-617.	1.3	113
57	Vitamin D deficiency and anemia in early chronic kidney disease. Kidney International, 2010, 77, 715-720.	2.6	112
58	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation, 2016, 100, 184-193.	0.5	110
59	Vitamin D Therapy in Individuals With Prehypertension or Hypertension. Circulation, 2015, 131, 254-262.	1.6	103
60	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	2.6	103
61	High-Sensitivity Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Risk of Incident Heart Failure in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 946-956.	3.0	101
62	Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 1140-1148.	3.0	98
63	FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Scientific Reports, 2017, 7, 1993.	1.6	97
64	Low Socioeconomic Status Associates with Higher Serum Phosphate Irrespective of Race. Journal of the American Society of Nephrology: JASN, 2010, 21, 1953-1960.	3.0	96
65	Obesity and Preeclampsia. Obstetrics and Gynecology, 2001, 98, 757-762.	1.2	95
66	First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 2003, 189, 171-176.	0.7	95
67	Targeting Vascular Calcification in Chronic Kidney Disease. JACC Basic To Translational Science, 2020, 5, 398-412.	1.9	95
68	Insulin Resistance and Alterations in Angiogenesis. Hypertension, 2004, 43, 988-992.	1.3	93
69	Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors forÂdeath in chronic kidney disease. Kidney International, 2017, 91, 711-719.	2.6	91
70	Food Access, Chronic Kidney Disease, and Hypertension in the U.S.. American Journal of Preventive Medicine, 2015, 49, 912-920.	1.6	89
71	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International, 2009, 76, 705-716.	2.6	87
72	Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology Dialysis Transplantation, 2012, 27, 3270-3278.	0.4	87

#	Article	IF	Citations
73	Mineral Metabolites and CKD Progression in African Americans. Journal of the American Society of Nephrology: JASN, 2013, 24, 125-135.	3.0	87
74	Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrology Dialysis Transplantation, 2014, 29, 2028-2035.	0.4	86
75	Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. American Journal of Kidney Diseases, 2019, 73, 344-353.	2.1	84
76	Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. Journal of the American Society of Nephrology: JASN, 2019, 30, 1096-1108.	3.0	83
77	Regulation and Effects of FGF23 in Chronic Kidney Disease. Annual Review of Physiology, 2020, 82, 365-390.	5.6	82
78	Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiology, 2016, 1, 548.	3.0	81
79	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Research and Clinical Practice, 2012, 97, 71-76.	1.1	78
80	Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. Journal of the American Society of Nephrology: JASN, 2017, 28, 1877-1885.	3.0	76
81	Fibroblast Growth Factor 23 in Patients Undergoing Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2688-2695.	2.2	74
82	FGF-23 Levels in Patients with AKI and Risk of Adverse Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1217-1223.	2.2	74
83	Persistent High Serum Bicarbonate and the Risk of Heart Failure in Patients With Chronic Kidney Disease (CKD): A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Heart Association, 2015, 4, .	1.6	74
84	Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1189-1196.	2.2	73
85	Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3779-3786.	1.8	71
86	Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney International, 2016, 89, 939-948.	2.6	71
87	Vitamin D Deficiency, Inflammation, and Albuminuria in Chronic Kidney Disease: Complex Interactions. , 2011, 21, 295-302.		68
88	Phosphate Homeostasis in CKD: Report of a Scientific Symposium Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2013, 62, 457-473.	2.1	67
89	Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	65
90	Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clinical Endocrinology, 2013, 79, 491-498.	1.2	64

#	Article	IF	Citations
91	Plasma FGF23 and the risk of stroke. Neurology, 2014, 82, 1700-1706.	1.5	64
92	Differential Risk of Hypertensive Disorders of Pregnancy among Hispanic Women. Journal of the American Society of Nephrology: JASN, 2004, 15, 1330-1338.	3.0	63
93	Safety and efficacy ofÂiron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrology Dialysis Transplantation, 2021, 36, 111-120.	0.4	61
94	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltosideâ€"a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 2256-2273.	1.1	61
95	Earlier Onset and Greater Severity of Disordered Mineral Metabolism in Diabetic Patients With Chronic Kidney Disease. Diabetes Care, 2012, 35, 994-1001.	4.3	59
96	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2019, 73, 806-814.	2.1	58
97	DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease. Bone Research, 2019, 7, 12.	5.4	57
98	Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1795-1803.	2.2	55
99	Klotho Variants and Chronic Hemodialysis Mortality. Journal of Bone and Mineral Research, 2009, 24, 1847-1855.	3.1	54
100	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. Journal of the American Society of Nephrology: JASN, 2019, 30, 1495-1504.	3.0	53
101	Genetic Variants Associated with Circulating Parathyroid Hormone. Journal of the American Society of Nephrology: JASN, 2017, 28, 1553-1565.	3.0	52
102	Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1181-1189.	2.2	51
103	Urban foodscape trends: Disparities in healthy food access in Chicago, 2007â€"2014. Health and Place, 2018, 52, 231-239.	1.5	49
104	Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2612-2619.	2.2	48
105	Higher net acid excretion is associated with a lower risk of kidney disease progression in patients withÂdiabetes. Kidney International, 2017, 91, 204-215.	2.6	47
106	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function inÂaÂmouse model of chronic kidney disease. Kidney International, 2019, 96, 1346-1358.	2.6	47
107	Insulin Resistance But Not Inflammation Is Associated With Gestational Hypertension. Hypertension, 2002, 40, 886-891.	1.3	46
108	Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 75, 235-244.	2.1	46

#	Article	IF	Citations
109	Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 77, 56-73.e1.	2.1	45
110	Daily Variability in Mineral Metabolites in CKD and Effects of Dietary Calcium and Calcitriol. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 820-828.	2.2	44
111	FGF23 Modifies the Relationship Between Vitamin D and Cardiac Remodeling. Circulation: Heart Failure, 2013, 6, 817-824.	1.6	44
112	Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 531-541.	2.2	43
113	Early Pregnancy Insulin Resistance and Subsequent Gestational Diabetes Mellitus. Diabetes Care, 2005, 28, 1207-1208.	4.3	42
114	Fibroblast growth factor 23 and the future of phosphorus management. Current Opinion in Nephrology and Hypertension, 2009, 18, 463-468.	1.0	42
115	A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 161-174.	3.0	42
116	N-terminal Pro-Bâ€"Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements. Clinical Chemistry, 2008, 54, 1339-1348.	1.5	40
117	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone, 2022, 154, 116202.	1.4	40
118	Impact of Poverty on Serum Phosphate Concentrations in the Third National Health and Nutrition Examination Survey. , 2011, 21, 140-148.		39
119	Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrology Dialysis Transplantation, 2011, 26, 1258-1265.	0.4	39
120	Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 487-490.	1.2	38
121	Dietary Phosphorus Restriction in Advanced Chronic Kidney Disease: Merits, Challenges, and Emerging Strategies. Seminars in Dialysis, 2010, 23, 401-406.	0.7	38
122	Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 3970-3977.	0.4	37
123	Fibroblast Growth Factor 23, High-Sensitivity Cardiac Troponin, and Left Ventricular Hypertrophy in CKD. American Journal of Kidney Diseases, 2013, 61, 67-73.	2.1	37
124	Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. Journal of the American Society of Nephrology: JASN, 2018, 29, 2583-2592.	3.0	35
125	Pulmonary Hypertension Subtypes and Mortality in CKD. American Journal of Kidney Diseases, 2020, 75, 713-724.	2.1	32
126	Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2128-2135.	2.2	31

#	Article	IF	Citations
127	Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L16-L26.	1.3	31
128	Clinical Research Career Development. Academic Medicine, 2002, 77, 1084-1088.	0.8	30
129	(1-34) Parathyroid Hormone Infusion Acutely Lowers Fibroblast Growth Factor 23 Concentrations in Adult Volunteers. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 139-145.	2.2	30
130	FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults. Hypertension, 2018, 72, 70-76.	1.3	30
131	Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. Nephrology Dialysis Transplantation, 2010, 25, 1335-1337.	0.4	29
132	Association of Serum Phosphorus Level With Anemia in Kidney Transplant Recipients. Transplantation, 2011, 91, 875-882.	0.5	29
133	Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2048-2053.	1.1	29
134	Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 545-553.	2.1	29
135	Mineral (Mal)Adaptation to Kidney Diseaseâ€"Young Investigator Award Address. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1875-1885.	2.2	28
136	Acid Load and Phosphorus Homeostasis in CKD. American Journal of Kidney Diseases, 2017, 70, 541-550.	2.1	28
137	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrology Dialysis Transplantation, 2019, 34, 339-346.	0.4	28
138	Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2010, 19, 335-342.	1.0	27
139	Expression of fgf23 and Âklotho in developing embryonic tissues and adult kidney of the zebrafish, Danio rerio. Nephrology Dialysis Transplantation, 2012, 27, 4314-4322.	0.4	27
140	Phosphate: a novel cardiovascular risk factor. European Heart Journal, 2013, 34, 1099-1101.	1.0	27
141	The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease. Canadian Journal of Cardiology, 2016, 32, 369-377.	0.8	27
142	Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 776-783.	2.2	27
143	Associations of Dietary Phosphorus Intake, Urinary Phosphate Excretion, and Fibroblast Growth Factor 23 With Vascular Stiffness in Chronic Kidney Disease. , 2013, 23, 12-20.		26
144	Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage. Stroke, 2016, 47, 923-928.	1.0	26

#	Article	IF	Citations
145	Genetic background influences cardiac phenotype in murine chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 1129-1137.	0.4	26
146	FGF23 and Nutritional Metabolism. Annual Review of Nutrition, 2017, 37, 247-268.	4.3	25
147	Vitamin D and Health Outcomes. JAMA - Journal of the American Medical Association, 2019, 322, 1866.	3.8	25
148	Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis. British Journal of Pharmacology, 2020, 177, 4400-4415.	2.7	25
149	Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Research, 2021, 9, 35.	5.4	24
150	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases, 2021, 77, 920-930.e1.	2.1	23
151	Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 29-38.	2.2	22
152	Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney International, 2021, 100, 1292-1302.	2.6	22
153	Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatric Transplantation, 2011, 15, 37-46.	0.5	21
154	Associations of Socioeconomic Status and Processed Food Intake With Serum Phosphorus Concentration in Community-Living Adults: The Multi-Ethnic Study of Atherosclerosis (MESA). , 2012, 22, 480-489.		21
155	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. Kidney International, 2013, 83, 789-791.	2.6	21
156	Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Scientific Reports, 2019, 9, 8877.	1.6	21
157	VITAMIN D IN HEALTH AND DISEASE: Beyond Minerals and Parathyroid Hormone: Role of Active Vitamin D in End-Stage Renal Disease. Seminars in Dialysis, 2005, 18, 302-306.	0.7	20
158	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. CKJ: Clinical Kidney Journal, 2020, 13, 75-84.	1.4	20
159	Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1009-1019.	1.8	20
160	Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry. Nephrology Dialysis Transplantation, 2015, 30, 630-635.	0.4	19
161	Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. Kidney International Reports, 2019, 4, 1598-1607.	0.4	19
162	Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 77, 907-919.	2.1	19

#	Article	IF	Citations
163	Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2246-2253.	1.8	18
164	Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1461-1469.	2.2	18
165	Integrating Research Training Into Residency: Tools of Human Investigation. Academic Medicine, 2009, 84, 1295-1300.	0.8	17
166	Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study. Kidney International Reports, 2019, 4, 80-93.	0.4	17
167	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 1836-1846.	3.0	17
168	Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2017, 32, gfw387.	0.4	16
169	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study. PLoS ONE, 2020, 15, e0226509.	1.1	16
170	Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney International, 2021, 99, 977-985.	2.6	16
171	Î±Klotho: FGF23 coreceptor and FGF23-regulating hormone. Journal of Clinical Investigation, 2012, 122, 4336-4339.	3.9	16
172	Needle in a Haystack. New England Journal of Medicine, 2006, 354, 68-73.	13.9	15
173	Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1673-1679.	1.8	15
174	Fibroblast Growth Factor-23, Heart Failure Risk, and Reninâ€“Angiotensinâ€“Aldosterone-System Blockade in Hypertension: The MESA Study. American Journal of Hypertension, 2019, 32, 18-25.	1.0	15
175	Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Advances in Therapy, 2021, 38, 3531-3549.	1.3	15
176	Diagnosis and Management of Mineral Metabolism in CKD. Journal of General Internal Medicine, 2010, 25, 710-716.	1.3	14
177	Genetic African Ancestry and Markers of Mineral Metabolism in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 653-662.	2.2	14
178	Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis. Cytokine, 2017, 91, 124-127.	1.4	14
179	Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study. PLoS ONE, 2018, 13, e0206839.	1.1	14
180	Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design. Nephrology Dialysis Transplantation, 2010, 25, 2368-2375.	0.4	13

#	Article	IF	Citations
181	Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. American Journal of Hypertension, 2017, 30, 822-829.	1.0	13
182	Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. Kidney International Reports, 2018, 3, 1467-1472.	0.4	13
183	Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study. American Journal of Nephrology, 2019, 49, 263-270.	1.4	13
184	Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2020, 75, 908-918.	2.1	13
185	Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middleâ€Aged Adults. Journal of the American Heart Association, 2021, 10, e020196.	1.6	12
186	Hunt for the culprit of cardiovascular injury in kidney disease: FigureÂ1. Cardiovascular Research, 2015, 108, 209-211.	1.8	11
187	Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. Nephrology Dialysis Transplantation, 2015, 30, 1534-1541.	0.4	11
188	Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4648-4657.	1.8	11
189	Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes. PLoS ONE, 2018, 13, e0203460.	1.1	11
190	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. American Journal of Kidney Diseases, 2019, 74, 771-781.	2.1	11
191	Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease. American Journal of Epidemiology, 2020, 189, 433-444.	1.6	11
192	Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. Therapeutic Innovation and Regulatory Science, 2020, 54, 1477-1488.	0.8	11
193	Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The <scp>FERWONâ€IDA</scp>/<scp>NEPHRO</scp> trials. American Journal of Hematology, 2021, 96, E11-E15.	2.0	11
194	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology, 2014, 53, 1613-1617.	0.9	10
195	Increasing Use of Vitamin D Supplementation in the Chronic Renal Insufficiency Cohort Study. , 2014, 24, 186-193.		10
196	When there will never be a randomized controlled trial. Kidney International, 2015, 88, 220-222.	2.6	10
197	GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. American Journal of Nephrology, 2019, 50, 105-114.	1.4	10
198	FGFR4 does not contribute to progression of chronic kidney disease. Scientific Reports, 2019, 9, 14023.	1.6	10

#	Article	IF	Citations
199	Anemia and Incident End-Stage Kidney Disease. Kidney360, 2020, 1, 623-630.	0.9	10
200	Racial Differences in the Associations Between Food Insecurity and Fibroblast Growth Factor 23 in the Coronary Artery Risk Development in Young Adults Study. , 2020, 30, 509-517.		10
201	Active Vitamin D and Survival. Journal of the American Society of Nephrology: JASN, 2008, 19, 1442-1443.	3.0	9
202	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. International Urology and Nephrology, 2012, 44, 1169-1175.	0.6	9
203	Asymptomatic Ventricular Arrhythmia and Clinical Outcomes in Chronic Kidney Disease: A Pilot Study. CardioRenal Medicine, 2017, 7, 66-73.	0.7	9
204	Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. Bone, 2020, 141, 115559.	1.4	9
205	Nephropathic Cystinosis: A Distinct Form of CKDâ€“Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. Journal of the American Society of Nephrology: JASN, 2020, 31, 2184-2192.	3.0	9
206	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 309-317.	0.7	9
207	Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic. JAMA - Journal of the American Medical Association, 2017, 317, 139.	3.8	8
208	Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry. Journal of Bone and Mineral Metabolism, 2017, 35, 666-674.	1.3	8
209	Association between patient race and staff resuscitation efforts after cardiac arrest in outpatient dialysis clinics: A study from the CARES surveillance group. Resuscitation, 2020, 156, 42-50.	1.3	8
210	Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 601-611.	3.0	8
211	A Physiologicâ€“Based Approach to the Evaluation of a Patient With Hyperphosphatemia. American Journal of Kidney Diseases, 2013, 61, 330-336.	2.1	7
212	The Biomarker Niche for Fibroblast Growth Factor 23 Testing in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 7-9.	3.0	7
213	Modifiers of Plasma 25-Hydroxyvitamin D and Chronic Kidney Disease Outcomes in Black Americans: The Jackson Heart Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2267-2276.	1.8	7
214	Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 2282-2289.	0.4	7
215	Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide. Kidney International Reports, 2018, 3, 364-373.	0.4	6
216	Chicago supermarket data and food access analytics in census tract shapefiles for 2007â€“2014. Data in Brief, 2018, 21, 2482-2488.	0.5	6

#	Article	IF	Citations
217	Metabolic Changes with Base-Loading in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1244-1246.	2.2	6
218	Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2019, 74, 203-212.	2.1	6
219	Time-Updated Changes in Estimated GFR and Proteinuria and Major Adverse Cardiac Events: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2022, 79, 36-44.e1.	2.1	6
220	Case 28-2005. New England Journal of Medicine, 2005, 353, 1148-1157.	13.9	5
221	FGF23. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1727-1729.	2.2	5
222	Second Chances in Mineral Metabolism. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1-3.	2.2	5
223	Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360, 2022, 3, 258-268.	0.9	5
224	Phosphate Metabolism and Fibroblast Growth Factor 23 in Chronic Kidney Disease. , 2013, , 285-308.		4
225	Does a rise in plasma erythropoietin after high-altitude exposureÂaffect FGF23 in healthy volunteers on a normal or low-phosphorus diet?. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1361-1367.	1.1	4
226	Echocardiography to Screen for Pulmonary Hypertension in CKD. Kidney International Reports, 2020, 5, 2275-2283.	0.4	4
227	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 1, 648-656.	0.9	4
228	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. American Journal of Kidney Diseases, 2020, 76, 842-850.	2.1	4
229	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Heart Journal, 2021, 245, 10-10.	1.2	4
230	Should activated vitamin D be used in patients with endâ€stage renal disease and low levels of parathyroid hormone?. Seminars in Dialysis, 2011, 24, 428-430.	0.7	3
231	Differential Effects of Vitamin D Receptor Agonists on Gene Expression in Neonatal Rat Cardiomyocytes. Cardiovascular Drugs and Therapy, 2011, 25, 215-222.	1.3	3
232	In Search of the Fountain of Youth. Journal of the American Society of Nephrology: JASN, 2014, 25, 2143-2145.	3.0	3
233	Editorial: awareness and prevention of intravenous ironâ€induced hypophosphataemia. Alimentary Pharmacology and Therapeutics, 2019, 50, 609-610.	1.9	3
234	Association of Fitness With Racial Differences in Chronic Kidney Disease. American Journal of Preventive Medicine, 2019, 57, 68-76.	1.6	3

#	Article	IF	Citations
235	Pivoting From PTH to FGF23 to Mend Breaking Hearts on Dialysis. Circulation Research, 2021, 128, 1626-1628.	2.0	3
236	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean. Kidney International Supplements, 2021, 11, e66-e76.	4.6	3
237	A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan. American Journal of Nephrology, 2022, 53, 226-239.	1.4	3
238	Something old, something new, something borrowed, something black. Current Opinion in Nephrology and Hypertension, 2017, 26, 241-242.	1.0	2
239	Statins at Dialysis Transitionâ€"Supportive but Not Sufficient. JAMA Network Open, 2018, 1, e182411.	2.8	2
240	Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos. Bone, 2018, 114, 278-284.	1.4	2
241	Fibroblast Growth Factor-23 and a Vegetarian Diet. , 2020, 30, 503-508.		2
242	Phosphate REINs in the Renoprotective Benefit of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1777-1779.	3.0	1
243	Partial Answers from Partial Klotho Deficiency. Journal of the American Society of Nephrology: JASN, 2012, 23, 1599-1601.	3.0	1
244	Mineral metabolism. Current Opinion in Nephrology and Hypertension, 2016, 25, 269-270.	1.0	1
245	Global Health Training Opportunities in North American Nephrology Fellowships. Kidney International Reports, 2019, 4, 904-907.	0.4	1
246	Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 7-9.	2.2	1
247	Kidney to bone via bedside to benchâ€¦and back?. Journal of Clinical Investigation, 2020, 130, 1106-1108.	3.9	1
248	Pruning the ricket thicket. Journal of Clinical Investigation, 2016, 126, 473-476.	3.9	1
249	Persistent Hypophosphatemia after Ferric Carboxymaltose Is Associated with Persistent Changes in Biomarkers of Bone Metabolism. Blood, 2020, 136, 13-14.	0.6	1
250	The Nephrology Immersion Classroom for Internal Medicine Residents. Kidney360, 2020, 1, 1060-1067.	0.9	1
251	Case of the month misdiagnosis. American Journal of Medicine, 2000, 108, 263.	0.6	0
252	Chronic kidney disease in patients with cognitive impairment: a marker of microvascular damage or an independent risk factor?. Aging Health, 2010, 6, 423-427.	0.3	0

#	Article	IF	Citations
253	The beehive and the merry-go-round in mineral metabolism. Current Opinion in Nephrology and Hypertension, 2011, 20, 329-330.	1.0	0
254	Common Genetic Determinants of Vitamin D Insufficiency: A Genome-Wide Association Study. Obstetrical and Gynecological Survey, 2011, 66, 91-93.	0.2	0
255	Contemporary Mineral Metabolism for Clinicians and Scientists: Introduction. Seminars in Nephrology, 2013, 33, 91-92.	0.6	0
256	Innovations in bones and stones. Current Opinion in Nephrology and Hypertension, 2013, 22, 369-370.	1.0	0
257	The pursuit of truth and beauty. Current Opinion in Nephrology and Hypertension, 2014, 23, 329-330.	1.0	0
258	Fibroblast Growth Factor-23 Fans the Flames of Heart andÂKidney Failure â^—. JACC: Heart Failure, 2015, 3, 840-842.	1.9	0
259	The Authors Reply. Kidney International, 2017, 91, 1518-1519.	2.6	0
260	A Patient With CKD Develops Cholestatic Liver Injury During aÂClinical Trial. Kidney International Reports, 2018, 3, 5-10.	0.4	0
261	Health Outcomes With Vitamin D Supplementationâ€”Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1619.	3.8	0
262	Noninvasive Risk Score to Screen for Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance in Diseases of Chronic Volume Overload. American Journal of Cardiology, 2021, 159, 113-120.	0.7	0
263	Title is missing!. , 2020, 15, e0226509.		0
264	Title is missing!. , 2020, 15, e0226509.		0
265	Title is missing!. , 2020, 15, e0226509.		0
266	Title is missing!. , 2020, 15, e0226509.		0
267	Title is missing!. , 2020, 15, e0226509.		0
268	Title is missing!. , 2020, 15, e0226509.		0